The Population Research Core (PopRC) is a new shared resource for the HCCC. The Population Research Core is designed to assist HCCC members in conducting the highest quality genetic, epidemiologic, behavioral, applied, and surveillance cancer research based on enhancing access to, and connection between, large population databases. Its basic function is to serve as a resource to HCCC investigators who want to extend research findings to specific populations and who want to explore other population-based research questions. More specifically, the Population Research Core provides access for HCCC to: ? lowa Cancer Registry surveillance data ? lowa and SEER tissue repositories ? lowa mortality database ? lowa voter registration database ? lowa driver's license database ? SEER-Medicare database ? lowa Medicaid Database ? Cancer Care Outcomes Research &Surveillance Consortium ? Health Effectiveness Research Center ? Agricultural Health Study ? Center for the Heatth Effects of Environmental Contamination ? lowa Cancer Consortium The Population Research Core includes staff based in institutional centers of expertise, with intimate knowledge of the resources of these centers and how to harness them. Despite being a new shared research resource, in 2009, the Population Research Core provided services to 18 HCCC members with peer reviewed funding including investigators who are members of all 6 programs.

Public Health Relevance

The ability to analyze large population-based databases, and equally importantly, link them to each other, is vital for many cancer researchers. The Population Research Core provides access to such data to cancer researchers, and also provides the expertise needed to utilize this data which would, otherwise, not be available.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA086862-13
Application #
8466225
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
13
Fiscal Year
2013
Total Cost
$86,742
Indirect Cost
$31,206
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Sabree, Shakoora; Berg, Daniel; Sato, Mariko (2018) Treatment of a pediatric patient with MET-amplified signet ring cell adenocarcinoma of the stomach with crizotinib. Pediatr Blood Cancer 65:e26984
Bharti, Sanjay Kumar; Sommers, Joshua A; Awate, Sanket et al. (2018) A minimal threshold of FANCJ helicase activity is required for its response to replication stress or double-strand break repair. Nucleic Acids Res 46:6238-6256
Reiner, Anne S; Sisti, Julia; John, Esther M et al. (2018) Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol 36:1513-1520
Liu, Q; Kulak, M V; Borcherding, N et al. (2018) A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene 37:687-694
Arthur, Rhonda; Wassertheil-Smoller, Sylvia; Manson, JoAnn E et al. (2018) The Combined Association of Modifiable Risk Factors with Breast Cancer Risk in the Women's Health Initiative. Cancer Prev Res (Phila) 11:317-326
Press, Robert H; Shu, Hui-Kuo G; Shim, Hyunsuk et al. (2018) The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. Int J Radiat Oncol Biol Phys 102:1219-1235
Viala, Marie; Chiba, Akiko; Thezenas, Simon et al. (2018) Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. BMC Cancer 18:770
Madsen, Mark T; Menda, Yusuf; O'Dorisio, Thomas M et al. (2018) Technical Note: Single time point dose estimate for exponential clearance. Med Phys 45:2318-2324
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Pryma, Daniel A; Chin, Bennett B; Noto, Richard B et al. (2018) Efficacy and Safety of High-Specific-Activity I-131 MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J Nucl Med :

Showing the most recent 10 out of 1080 publications